Found 270 Enz. Inhib. hit(s) with all data for entry = 11241 
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 0.680nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.940nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3.10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
